Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.

Mankind Pharma Limited

Mankind Pharma is an Indian pharmaceutical company incorporated in 1995. It is the self-described 4th largest pharmaceutical company in India by domestic sales, focusing on producing pharmaceutical products.

Mankind Pharma

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries.

Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products.

Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients.

Mankind strongly believes and follows its Core Values:

𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External
𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products
𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements
𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone
𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities
𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

MANKIND PHARMA LTD

A tribute to the compassionate heroes who choose to give the gift of life to those in need. #MankindPharma believes that choosing to be an organ donor is an act of spreading kindness. With only 0.86 donors per million, alarmingly low number of registered donors in our country, we urge you to spark a wave of change and choose to be an organ donor today.

Share this video to spread awareness!

#WorldOrganDonationDay #OrganDonation #SpreadingKindness #ServingLife #HealthIsWealth #Mankind #Healthcare #Pharma #Pharmaceutical #Health

Mankind Pharma is pleased to announce its steady performance for this quarter, reflecting our unwavering commitment to innovative healthcare solutions. The company remains focused on expanding to chronic therapies and entering high entry barrier segments with the acquisition of Bharat Serums and Vaccines Limited, to ensure sustained growth and industry leadership.

#MankindPharma #ServingLife

Rajeev Juneja  VC and Managing Director MANKIND PHARMA LTD  In conversation with CNBC-TV18  

BSV’s acquisition marks a pivotal milestone in Mankind’s journey. This strategic partnership solidifies our position as the #1 leader in Gynecology and propels us into a leadership role in women's health and fertility. 

BSV's established Specialty R&D Tech Platforms with complex portfolio across Women’s health, Fertility, critical care and Immunoglobulin segment perfectly aligns with Mankind Pharma's strategic vision to expand its footprint in high entry barrier portfolio.

By combining our strengths, we're creating a formidable force dedicated to delivering innovative solutions and improving the lives of millions.

#MankindPharma #BSVAcquisition #WomensHealth #Fertility #Healthcare #Leadership #Innovation

Watch now:

https://lnkd.in/g85RkxBr

https://lnkd.in/g52ahdYF

For an infection with no known cure,  let’s vow this #WorldHepatitisDay to spread awareness and lower our chances of the deadly infection.

#MankindPharma #ServingLife #SpreadingKindness #HealthIsWealth #Mankind #Healthcare #Pharma #Pharmaceutical #Health

#Budget2024 aligns with #ViksitBharat vision for healthcare. We welcome the focus on medical education, prevention & infrastructure, the allocation for long-term R&D financing for pharma, the bio-manufacturing scheme, and the customs duty exemption for cancer drugs. Overall, a promising direction for a more resilient & accessible healthcare system in India: Mr Arjun Juneja, Chair, FICCI Pharma Committee and COO, MANKIND PHARMA LTD.

#BudgetWithFICCI

In Monsoon, your high fever could be dengue! Skip the guesswork. Stay a step ahead with Rapid News Dengue Home Detection Kit – because hashtag
#MonsoonNahiYeDengueSeasonHai

Buy from your nearest chemist, Apollo Pharmacy, Frank Ross, Amazon, Flipkart & Tata 1 mg. 

#dengue #monsoon #test #detection #testkit #denguekit #season #rain #rapidnewskit #MankindPharma #SevingLife

	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
revenue	58.65B -	62.14B 5.95%	77.82B 25.22%	87.43B 12.35%	103.35B 18.21%
cost of revenue	19.23B -	18.25B 5.12%	24.70B 35.34%	53.54B 116.78%	32.10B 40.06%
gross profit	39.42B -	43.89B 11.35%	53.12B 21.01%	33.88B 36.21%	71.25B 110.28%
selling and marketing expenses	3.02B -	4.47B 47.98%	5.34B 19.32%		7.29B -
general and administrative expenses	529.69M -	748.78M 41.36%	1.25B 66.52%		2.61B -
selling general and administrative expenses	3.55B -	5.22B 47.00%	6.59B 26.09%	14.69B 123.02%	23.15B 57.64%
research and development expenses		1.71B -	2.13B 24.98%	1.88B 11.84%	2.23B 18.30%
other expenses	97.27M -	100.20M 3.01%	130.01M 29.75%	-1.13B 972.76%	2.81B 347.52%
cost and expenses	43.96B -	46.08B 4.81%	59.03B 28.11%	71.25B 20.69%	81.98B 15.06%
operating expenses	24.73B -	27.83B 12.53%	34.33B 23.37%	17.70B 48.44%	49.88B 181.76%
interest expense	219.23M -	193.03M 11.95%	557.80M 188.97%	419.88M 24.73%	335.32M 20.14%
ebitda	16.13B -	17.85B 10.64%	20.90B 17.12%	19.44B 6.99%	28.31B 45.65%
operating income	15.14B -	16.66B 10.02%	19.23B 15.48%	16.18B 15.88%	24.33B 50.37%
depreciation and amortization	990.59M -	1.19B 20.10%	1.67B 40.05%	3.26B 95.57%	167.90K 99.99%
total other income expenses net	-761.22M -	260.78M 134.26%	512.71M 96.61%	408.39M 20.35%	-335.32M 182.11%
income before tax	14.38B -	16.92B 17.66%	19.75B 16.73%	16.59B 15.99%	23.99B 44.64%
income tax expense	3.82B -	3.99B 4.45%	5.22B 30.88%	3.62B 30.69%	4.58B 26.56%
net income	10.30B -	12.65B 22.81%	14.33B 13.28%	12.82B 10.58%	19.13B 49.23%
weighted average shs out	400.59M -	400.59M 0%	400.59M 0%	400.59M 0%	400.59M 0.00%
weighted average shs out dil	400.59M -	400.59M 0%	400.59M 0%	400.59M 0.00%	401.20M 0.15%
eps	25.72 -	31.59 22.82%	35.78 13.26%	32 10.56%	47.75 49.22%
epsdiluted	25.72 -	31.59 22.82%	35.78 13.26%	32 10.56%	47.68 49%

MANK

COM:MANKINDPHARMA

Mankind Pharma

Last Close

2,574.40

21/11 10:00

Market Cap

848.24B

Beta: -

Volume Today

275.52K

Avg: -

Preview